FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:246-254 January 25, 1996 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A peptide inhibiting the release of growth hormone was originally detected accidentally during studies of the distribution of growth hormone–releasing factor in the hypothalamus of rats.¹ This peptide, called somatostatin, proved to be a cyclic peptide consisting of 14 amino acids.² Subsequent work has considerably expanded this initially simple concept of somatostatin as a peptide whose main function is the regulation of growth hormone secretion.³ Today, somatostatin is best regarded as a phylogenetically ancient, multigene family of peptides with two important bioactive products: somatostatin-14 and somatostatin-28, the latter a congener of somatostatin-14 extended at the N-terminal.^3,4

Like other peptide hormones, . . . [Full Text of this Article]

Somatostatin Receptors

Somatostatin Analogues

Treatment of Hormone-Secreting Tumors

Acromegaly

Thyrotropin-Secreting Pituitary Adenomas

Nonsecretory Pituitary Adenomas

Corticotropin-Secreting Pituitary Adenomas

Pancreatic Islet-Cell Tumors

Carcinoid Tumors

Gastrointestinal Indications

Potential Role in Oncologic Treatment

Adverse Effects of Octreotide

New Forms of Somatostatin Analogues

Conclusions

Source Information

From the Department of Medicine, Erasmus University, Rotterdam, the Netherlands.

Address reprint requests to Dr. Lamberts at University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD Rotterdam, the Netherlands.

References

This article has been cited by other articles:

• Colao, A., Auriemma, R. S., Galdiero, M., Lombardi, G., Pivonello, R. (2009). Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. J. Clin. Endocrinol. Metab. 94: 3746-3756 [Abstract] [Full Text]  
• Ning, S., Knox, S. J, Harsh, G. R, Culler, M. D, Katznelson, L. (2009). Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer 16: 1045-1055 [Abstract] [Full Text]  
• Giustina, A., Bonadonna, S., Bugari, G., Colao, A., Cozzi, R., Cannavo, S., de Marinis, L., degli Uberti, E., Bogazzi, F., Mazziotti, G., Minuto, F., Montini, M., Ghigo, E. (2009). High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161: 331-338 [Abstract] [Full Text]  
• Mazziotti, G., Floriani, I., Bonadonna, S., Torri, V., Chanson, P., Giustina, A. (2009). Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. J. Clin. Endocrinol. Metab. 94: 1500-1508 [Abstract] [Full Text]  
• Horiguchi, K., Yamada, M., Satoh, T., Hashimoto, K., Hirato, J., Tosaka, M., Yamada, S., Mori, M. (2009). Transcriptional Activation of the Mixed Lineage Leukemia-p27Kip1 Pathway by a Somatostatin Analogue. Clin. Cancer Res. 15: 2620-2629 [Abstract] [Full Text]  
• Weber, C., Zulian, G. B. (2009). Malignant Irreversible Intestinal Obstruction: The Powerful Association of Octreotide to Corticosteroids, Antiemetics, and Analgesics. AM J HOSP PALLIAT CARE 26: 84-88 [Abstract]  
• Grant, M., Alturaihi, H., Jaquet, P., Collier, B., Kumar, U. (2008). Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization. Mol. Endocrinol. 22: 2278-2292 [Abstract] [Full Text]  
• Ching, Y. A., Gura, K., Modi, B., Jaksic, T. (2007). Pediatric Intestinal Failure: Nutrition, Pharmacologic, and Surgical Approaches. Nutr Clin Pract 22: 653-663 [Abstract] [Full Text]  
• Oyen, W. J. G., Bodei, L., Giammarile, F., Maecke, H. R., Tennvall, J., Luster, M., Brans, B. (2007). Targeted therapy in nuclear medicine current status and future prospects. Ann Oncol 18: 1782-1792 [Abstract] [Full Text]  
• Gibney, J., Healy, M.-L., Sonksen, P. H. (2007). The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport. Endocr. Rev. 28: 603-624 [Abstract] [Full Text]  
• Rahmi, G., Malka, D., Tomasic, G., Dromain, C., Ducreux, M., Boige, V. (2007). Complete, Long-Standing Regression of Hepatocellular Carcinoma After Somatostatin Analogue Treatment. JCO 25: e15-e16 [Full Text]  
• van der Hoek, J., Lamberts, S. W J, Hofland, L. J (2007). Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156: S45-S51 [Abstract] [Full Text]  
• Fazio, N, de Braud, F, Delle Fave, G, Oberg, K (2007). Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. Ann Oncol 18: 13-19 [Abstract] [Full Text]  
• Melmed, S. (2006). Acromegaly. NEJM 355: 2558-2573 [Full Text]  
• Schwarz, E. R., Jammula, P., Gupta, R., Rosanio, S. (2006). A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both?. J CARDIOVASC PHARMACOL THER 11: 232-244 [Abstract]  
• Hubina, E., Nanzer, A. M, Hanson, M. R, Ciccarelli, E., Losa, M., Gaia, D., Papotti, M., Terreni, M. R., Khalaf, S., Jordan, S., Czirjak, S., Hanzely, Z., Nagy, G. M, Goth, M. I, Grossman, A. B, Korbonits, M. (2006). Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.. Eur J Endocrinol 155: 371-379 [Abstract] [Full Text]  
• Paran, D, Bernheim, J, Golan, I, Caspi, D, Bernheim, J, Benchetrit, S (2006). Somatostatin Treatment Attenuates Proteinuria and Prevents Weight Loss in NZB/W F1 Mice. Lupus 15: 526-531 [Abstract]  
• Soderstrom, J, Murray, L, Daly, F F S, Little, M (2006). Toxicology case of the month: oral hypoglycaemic overdose.. Emerg. Med. J. 23: 565-567 [Abstract] [Full Text]  
• Colao, A., Pivonello, R., Auriemma, R. S., Briganti, F., Galdiero, M., Tortora, F., Caranci, F., Cirillo, S., Lombardi, G. (2006). Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients. J. Clin. Endocrinol. Metab. 91: 2112-2118 [Abstract] [Full Text]  
• Engstrom, M., Savola, J.-M., Wurster, S. (2006). Differential Efficacies of Somatostatin Receptor Agonists for G-Protein Activation and Desensitization of Somatostatin Receptor Subtype 4-Mediated Responses. J. Pharmacol. Exp. Ther. 316: 1262-1268 [Abstract] [Full Text]  
• Pokrajac, A., Claridge, A. G, Shakoor, S K A., Trainer, P. J (2006). The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154: 267-274 [Abstract] [Full Text]  
• Vitale, G., de Herder, W. W., van Koetsveld, P. M., Waaijers, M., Schoordijk, W., Croze, E., Colao, A., Lamberts, S. W.J., Hofland, L. J. (2006). IFN-{beta} Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro. Cancer Res. 66: 554-562 [Abstract] [Full Text]  
• de Herder, W. W, Taal, H R., Uitterlinden, P., Feelders, R. A, Janssen, J. A M J L, van der Lely, A.-J. (2005). Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153: 67-71 [Abstract] [Full Text]  
• Astruc, B., Marbach, P., Bouterfa, H., Denot, C., Safari, M., Vitaliti, A., Sheppard, M. (2005). Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles. J Clin Pharmacol 45: 836-844 [Abstract] [Full Text]  
• Filosso, P. L., Ruffini, E., Oliaro, A., Rena, O., Casadio, C., Mancuso, M., Turello, D., Cristofori, R. C., Maggi, G. (2005). Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J. Thorac. Cardiovasc. Surg. 129: 819-824 [Abstract] [Full Text]  
• Delaunoit, T., Rubin, J., Neczyporenko, F., Erlichman, C., Hobday, T. J. (2005). Somatostatin Analogues in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Mayo Clin Proc. 80: 502-506 [Abstract]  
• Bevan, J. S. (2005). The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly. J. Clin. Endocrinol. Metab. 90: 1856-1863 [Abstract] [Full Text]  
• Zuetenhorst, J. M., Taal, B. G. (2005). Metastatic Carcinoid Tumors: A Clinical Review. The Oncologist 10: 123-131 [Abstract] [Full Text]  
• Buchsbaum, D. J., Chaudhuri, T. R., Zinn, K. R. (2005). Radiotargeted Gene Therapy. JNM 46: 179S-186S [Abstract] [Full Text]  
• Gugger, M, Waser, B, Kappeler, A, Schonbrunn, A, Reubi, J C (2004). Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut 53: 1431-1436 [Abstract] [Full Text]  
• Pereira, J., Phan, T. (2004). Management of Bleeding in Patients with Advanced Cancer. The Oncologist 9: 561-570 [Abstract] [Full Text]  
• Makrilakis, K., Pavlatos, S., Giannikopoulos, G., Toubanakis, C., Katsilambros, N. (2004). Successful Octreotide Treatment of Chylous Pleural Effusion and Lymphedema in the Yellow Nail Syndrome. ANN INTERN MED 141: 246-247 [Full Text]  
• Kaltsas, G. A., Besser, G. M., Grossman, A. B. (2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev. 25: 458-511 [Abstract] [Full Text]  
• Oberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E. A., Wiedenmann, B. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15: 966-973 [Abstract] [Full Text]  
• Tulipano, G., Stumm, R., Pfeiffer, M., Kreienkamp, H.-J., Hollt, V., Schulz, S. (2004). Differential {beta}-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor Subtypes. J. Biol. Chem. 279: 21374-21382 [Abstract] [Full Text]  
• Hofland, L. J., van der Hoek, J., van Koetsveld, P. M., de Herder, W. W., Waaijers, M., Sprij-Mooij, D., Bruns, C., Weckbecker, G., Feelders, R., van der Lely, A.-J., Beckers, A., Lamberts, S. W. J. (2004). The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro. J. Clin. Endocrinol. Metab. 89: 1577-1585 [Abstract] [Full Text]  
• Colao, A., Ferone, D., Marzullo, P., Lombardi, G. (2004). Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr. Rev. 25: 102-152 [Abstract] [Full Text]  
• Dilger, J. A., Rho, E. H., Que, F. G., Sprung, J. (2004). Octreotide-Induced Bradycardia and Heart Block During Surgical Resection of a Carcinoid Tumor. Anesth. Analg. 98: 318-320 [Abstract] [Full Text]  
• Bertherat, J., Tenenbaum, F., Perlemoine, K., Videau, C., Alberini, J. L., Richard, B., Dousset, B., Bertagna, X., Epelbaum, J. (2003). Somatostatin Receptors 2 and 5 Are the Major Somatostatin Receptors in Insulinomas: An in Vivo and in Vitro Study. J. Clin. Endocrinol. Metab. 88: 5353-5360 [Abstract] [Full Text]  
• Reubi, J. C. (2003). Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy. Endocr. Rev. 24: 389-427 [Abstract] [Full Text]  
• Faiss, S., Pape, U.-F., Bohmig, M., Dorffel, Y., Mansmann, U., Golder, W., Riecken, E. O., Wiedenmann, B. (2003). Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors--The International Lanreotide and Interferon Alfa Study Group. JCO 21: 2689-2696 [Abstract] [Full Text]  
• Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., Xiong, X. (2003). Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial. J. Clin. Endocrinol. Metab. 88: 2586-2592 [Abstract] [Full Text]  
• Gibney, J., Healy, M. L., Stolinski, M., Bowes, S. B., Pentecost, C., Breen, L., McMillan, C., Russell-Jones, D. L., Sonksen, P. H., Umpleby, A. M. (2003). Effect of Growth Hormone (GH) on Glycerol and Free Fatty Acid Metabolism during Exhaustive Exercise in GH-Deficient Adults. J. Clin. Endocrinol. Metab. 88: 1792-1797 [Abstract] [Full Text]  
• Merza, Z (2003). Modern treatment of acromegaly. Postgrad. Med. J. 79: 189-194 [Abstract] [Full Text]  
• Moller, J. E., Connolly, H. M., Rubin, J., Seward, J. B., Modesto, K., Pellikka, P. A. (2003). Factors Associated with Progression of Carcinoid Heart Disease. NEJM 348: 1005-1015 [Abstract] [Full Text]  
• Ardjomand, N., Ardjomand, N., Schaffler, G., Radner, H., El-Shabrawi, Y. (2003). Expression of Somatostatin Receptors in Uveal Melanomas. IOVS 44: 980-987 [Abstract] [Full Text]  
• Doyle, M. E., Egan, J. M. (2003). Pharmacological Agents That Directly Modulate Insulin Secretion. Pharmacol. Rev. 55: 105-131 [Abstract] [Full Text]  
• Hofland, L. J., Lamberts, S. W. J. (2003). The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance. Endocr. Rev. 24: 28-47 [Abstract] [Full Text]  
• Marcora, S, Lemmey, A, Maddison, P, Paran, D, Elkayam, O (2002). Probable adverse effects of long term use of somatostatin analogues in patients with RA. Ann Rheum Dis 61: 1117-1117 [Full Text]  
• Ferone, D., Pivonello, R., van Hagen, P. M., Dalm, V. A. S. H., Lichtenauer-Kaligis, E. G. R., Waaijers, M., van Koetsveld, P. M., Mooy, D. M., Colao, A., Minuto, F., Lamberts, S. W. J., Hofland, L. J. (2002). Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am. J. Physiol. Endocrinol. Metab. 283: E1056-E1066 [Abstract] [Full Text]  
• Kopchick, J. J., Parkinson, C., Stevens, E. C., Trainer, P. J. (2002). Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly. Endocr. Rev. 23: 623-646 [Abstract] [Full Text]  
• Weckbecker, G., Briner, U., Lewis, I., Bruns, C. (2002). SOM230: A New Somatostatin Peptidomimetic with Potent Inhibitory Effects on the Growth Hormone/Insulin-Like Growth Factor-I Axis in Rats, Primates, and Dogs. Endocrinology 143: 4123-4130 [Abstract] [Full Text]  
• Melmed, S., Casanueva, F. F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Vance, M. L., Werder, K. V., Wass, J., Giustina, A. (2002). Guidelines for Acromegaly Management. J. Clin. Endocrinol. Metab. 87: 4054-4058 [Full Text]  
• Chu, J., Wang, R. Y., Hill, N. S. (2002). Update in Clinical Toxicology. Am. J. Respir. Crit. Care Med. 166: 9-15 [Full Text]  
• Freda, P. U. (2002). Somatostatin Analogs in Acromegaly. J. Clin. Endocrinol. Metab. 87: 3013-3018 [Full Text]  
• Le Pimpec-Barthes, F., D'Attellis, N., Dujon, A., Legman, P., Riquet, M. (2002). Chylothorax complicating pulmonary resection. Ann. Thorac. Surg. 73: 1714-1719 [Abstract] [Full Text]  
• Woodmansee, W. W., Mouser, R. L., Gordon, D. F., Dowding, J. M., Wood, W. M., Ridgway, E. C. (2002). Mutational Analysis of the Mouse Somatostatin Receptor Type 5 Gene Promoter. Endocrinology 143: 2268-2276 [Abstract] [Full Text]  
• Paglia, F., Dionisi, S., Minisola, S., Seufert, J., Jakob, F. (2002). Octreotide for Tumor-Induced Osteomalacia. NEJM 346: 1748-1749 [Full Text]  
• Waldherr, C., Pless, M., Maecke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A., Mueller-Brand, J. (2002). Tumor Response and Clinical Benefit in Neuroendocrine Tumors After 7.4 GBq 90Y-DOTATOC. JNM 43: 610-616 [Abstract] [Full Text]  
• Parkinson, C., Drake, W. M., Roberts, M. E., Meeran, K., Besser, G. M., Trainer, P. J. (2002). A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal. J. Clin. Endocrinol. Metab. 87: 1797-1804 [Abstract] [Full Text]  
• Caron, Ph., Beckers, A., Cullen, D. R., Goth, M. I., Gutt, B., Laurberg, P., Pico, A. M., Valimaki, M., Zgliczynski, W. (2002). Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly. J. Clin. Endocrinol. Metab. 87: 99-104 [Abstract] [Full Text]  
• Seufert, J., Ebert, K., Muller, J., Eulert, J., Hendrich, C., Werner, E., Schutze, N., Schulz, G., Kenn, W., Richtmann, H., Palitzsch, K.-D., Jakob, F. (2001). Octreotide Therapy for Tumor-Induced Osteomalacia. NEJM 345: 1883-1888 [Full Text]  
• Hesse, U, Ysebaert, D, de Hemptinne, B (2001). Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 49: iv11-20 [Abstract] [Full Text]  
• Gouillat, C, Gigot, J-F (2001). Pancreatic surgical complications--the case for prophylaxis. Gut 49: iv29-35 [Abstract] [Full Text]  
• Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I., Lombardi, G. (2001). Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. J. Clin. Endocrinol. Metab. 86: 2779-2786 [Abstract] [Full Text]  
• Afargan, M., Janson, E. T., Gelerman, G., Rosenfeld, R., Ziv, O., Karpov, O., Wolf, A., Bracha, M., Shohat, D., Liapakis, G., Gilon, C., Hoffman, A., Stephensky, D., Oberg, K. (2001). Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin. Endocrinology 142: 477-486 [Abstract] [Full Text]  
• Ferone, D., Pivonello, R., Van Hagen, P. M., Waaijers, M., Zuijderwijk, J., Colao, A., Lombardi, G., Bogers, A. J. J. C., Lamberts, S. W. J., Hofland, L. J. (2000). Age-related decrease of somatostatin receptor number in the normal human thymus. Am. J. Physiol. Endocrinol. Metab. 279: E791-E798 [Abstract] [Full Text]  
• Chowers, Y., Cahalon, L., Lahav, M., Schor, H., Tal, R., Bar-Meir, S., Levite, M. (2000). Somatostatin Through Its Specific Receptor Inhibits Spontaneous and TNF-{alpha}- and Bacteria-Induced IL-8 and IL-1{beta} Secretion from Intestinal Epithelial Cells. J. Immunol. 165: 2955-2961 [Abstract] [Full Text]  
• Gilbar, P. J. (2000). The role of octreotide in symptom management in oncology and palliative care. J Oncol Pharm Pract 6: 81-91 [Abstract]  
• Burch, P. A., Block, M., Schroeder, G., Kugler, J. W., Sargent, D. J., Braich, T. A., Mailliard, J. A., Michalak, J. C., Hatfield, A. K., Wright, K., Kuross, S. A. (2000). Phase III Evaluation of Octreotide versus Chemotherapy with 5-Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study. Clin. Cancer Res. 6: 3486-3492 [Abstract] [Full Text]  
• Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., Friend, K. E. (2000). The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth. Endocr. Rev. 21: 215-244 [Abstract] [Full Text]  
• Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A.J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., Besser, G. M., Scarlett, J. A. (2000). Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant. NEJM 342: 1171-1177 [Abstract] [Full Text]  
• Rocheville, M., Lange, D. C., Kumar, U., Sasi, R., Patel, R. C., Patel, Y. C. (2000). Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers. J. Biol. Chem. 275: 7862-7869 [Abstract] [Full Text]  
• Giustina, A., Barkan, A., Casanueva, F. F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., von Werder, K., Melmed, S. (2000). Criteria for Cure of Acromegaly: A Consensus Statement{dagger}. J. Clin. Endocrinol. Metab. 85: 526-529 [Abstract] [Full Text]  
• Smith-Jones, P. M., Bischof, C., Leimer, M., Gludovacz, D., Angelberger, P., Pangerl, T., Peck-Radosavljevic, M., Hamilton, G., Kaserer, K., Kofler, A., Schlagbauer-Wadl, H., Traub, T., Virgolini, I. (1999). DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy. Endocrinology 140: 5136-5148 [Abstract] [Full Text]  
• Hukovic, N., Rocheville, M., Kumar, U., Sasi, R., Khare, S., Patel, Y. C. (1999). Agonist-dependent Up-regulation of Human Somatostatin Receptor Type 1 Requires Molecular Signals in the Cytoplasmic C-tail. J. Biol. Chem. 274: 24550-24558 [Abstract] [Full Text]  
• Cairns, W., Malone, R. (1999). Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 13: 429-430  
• Corleto, V. D., Weber, H. C., Jensen, R. T. (1999). Expression of somatostatin receptor subtypes on guinea pig gastric and colonic smooth muscle cells. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G235-G244 [Abstract] [Full Text]  
• Wymenga, A.N.M., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J.D.G., Fiasse, R.H., Valimaki, M.J., Renstrup, J., de Vries, E.G.E., Oberg, K.E. (1999). Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms. JCO 17: 1111-1111 [Abstract] [Full Text]  
• Hofland, L.J., Liu, Q., van Koetsveld, P.M., Zuijderwijk, J., van der Ham, F., de Krijger, R.R., Schonbrunn, A., Lamberts, S.W.J. (1999). Immunohistochemical Detection of Somatostatin Receptor Subtypes sst1 and sst2A in Human Somatostatin Receptor Positive Tumors. J. Clin. Endocrinol. Metab. 84: 775-780 [Abstract] [Full Text]  
• Swearingen, B., Barker, F. G. II, Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. McL., Zervas, N. T. (1998). Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly. J. Clin. Endocrinol. Metab. 83: 3419-3426 [Abstract] [Full Text]  
• Freda, P. U., Wardlaw, S. L. (1998). Editorial: Primary Medical Therapy for Acromegaly. J. Clin. Endocrinol. Metab. 83: 3031-3033 [Full Text]  
• Newman, C. B., Melmed, S., George, A., Torigian, D., Duhaney, M., Snyder, P., Young, W., Klibanski, A., Molitch, M. E., Gagel, R., Sheeler, L., Cook, D., Malarkey, W., Jackson, I., Vance, M. L., Barkan, A., Frohman, L., Kleinberg, D. L. (1998). Octreotide as Primary Therapy for Acromegaly. J. Clin. Endocrinol. Metab. 83: 3034-3040 [Abstract] [Full Text]  
• Hukovic, N., Panetta, R., Kumar, U., Rocheville, M., Patel, Y. C. (1998). The Cytoplasmic Tail of the Human Somatostatin Receptor Type 5 Is Crucial for Interaction with Adenylyl Cyclase and in Mediating Desensitization and Internalization. J. Biol. Chem. 273: 21416-21422 [Abstract] [Full Text]  
• Colao, A., Marzullo, P., Vallone, G., Marinò, V., Annecchino, M., Ferone, D., de Brasi, D., Scarpa, R., Oriente, P., Lombardi, G. (1998). Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. J. Clin. Endocrinol. Metab. 83: 2121-2125 [Abstract] [Full Text]  
• (1998). Can Octreotide Be Added to Parenteral Nutrition Solutions? Point--Counterpoint. Nutr Clin Pract 13: 84-88  
• SHOUVAL, D (1998). Octreotide in hepatocellular carcinoma. Gut 42: 316-318 [Full Text]  
• Kouroumalis, E, Skordilis, P, Thermos, K, Vasilaki, A, Moschandrea, J, Manousos, O N (1998). Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42: 442-447 [Abstract] [Full Text]  
• Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R.-Z., Csernus, V., Kovacs, M., Koppan, M., Szepeshazi, K., Kahan, Z. (1998). Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA 95: 1794-1799 [Abstract] [Full Text]  
• Goumas, P., Naxakis, S., Christopoulou, A., Chrysanthopoulos, C., Nikolopoulou, V., Kalofonos, H. P. (1998). Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea. The Oncologist 3: 50-53 [Abstract] [Full Text]  
• Colao, A., Ferone, D., Cappabianca, P., del Basso De Caro, M. L., Marzullo, P., Monticelli, A., Alfieri, A., Merola, B., CalI, A., de Divitiis, E., Lombardi, G. (1997). Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly. J. Clin. Endocrinol. Metab. 82: 3308-3314 [Abstract] [Full Text]  
• von Essen, R., Ostermaier, R., Grube, E., Maurer, W., Tebbe, U., Erbel, R., Roth, M., Oel, W., Brom, J., Weidinger, G., Investigators, f. t. V. (1997). Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty : Results of the VERAS Study. Circulation 96: 1482-1487 [Abstract] [Full Text]  
• Colao, A., Merola, B., Ferone, D., Lombardi, G. (1997). Acromegaly. J. Clin. Endocrinol. Metab. 82: 2777-2781 [Full Text]  
• Tentler, J. J., Hadcock, J. R., Gutierrez-Hartmann, A. (1997). Somatostatin Acts by Inhibiting the Cyclic 3',5'-Adenosine Monophosphate (cAMP)/Protein Kinase A Pathway, cAMP Response Element-Binding Protein (CREB) Phosphorylation, and CREB Transcription Potency. Mol. Endocrinol. 11: 859-866 [Abstract] [Full Text]  
• Hipkin, R. W., Friedman, J., Clark, R. B., Eppler, C. M., Schonbrunn, A. (1997). Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin Receptor. J. Biol. Chem. 272: 13869-13876 [Abstract] [Full Text]  
• Colao, A., Ferone, D., Marzullo, P., Di Sarno, A., Cerbone, G., Sarnacchiaro, F., Cirillo, S., Merola, B., Lombardi, G. (1997). Effect of Different Dopaminergic Agents in the Treatment of Acromegaly. J. Clin. Endocrinol. Metab. 82: 518-523 [Abstract] [Full Text]  
• Palmieri, G., Lastoria, S., Colao, A., Vergara, E., Varrella, P., Biondi, E., Selleri, C., Catalano, L., Lombardi, G., Bianco, A. R., Salvatore, M. (1997). Successful Treatment of a Patient with a Thymoma and Pure Red-Cell Aplasia with Octreotide and Prednisone. NEJM 336: 263-265 [Full Text]  
• Robbins, R. J. (1997). Depot Somatostatin Analogs--A New First Line Therapy for Acromegaly. J. Clin. Endocrinol. Metab. 82: 15-17 [Full Text]